The results of our current study are in agreement with earlier studies with A. soehngenii in metabolic syndrome subjects, demonstrating improvements in insulin sensitivity and reduction of blood pressure and addressing the mode of action.25,26 Moreover, our current study has improved robustness due to the larger sample size and the use of a placebo group, while complying with current clinical practices including the use of the state-of-the art CGM with a 12-week intervention and 4-week follow-up washout period with longitudinal sampling. This evidence concerns the gene INS and metabolic syndrome.